Contrast-Enhanced Stereotactic Biopsy (CESB): Patient selection and practical considerations

M. B.I. Lobbes; J. Theunissen; A. Valentijn-Morsing; Y. Vissers; L. Bouwman

doi:10.1016/j.ejrad.2024.111768

Contrast-Enhanced Stereotactic Biopsy (CESB): Patient selection and practical considerations

M. B.I. Lobbes^*, J. Theunissen, A. Valentijn-Morsing, Y. Vissers, L. Bouwman

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Abstract

Since its introduction in 2012, contrast-enhanced mammography (CEM) has shown increased clinical relevance as a diagnostic tool in breast imaging. Its diagnostic accuracy is on par with breast MRI, rendering it a viable and potentially cost-effective alternative for breast MRI indications, especially in areas with lower accessibility to MRI. Like MRI, CEM occasionally shows ‘CEM-only’ lesions, i.e., areas of contrast enhancement without corresponding findings on low-energy images, ultrasound, or digital tomosynthesis. The current workaround usually consists of performing MRI-guided biopsy. However, contrast-enhanced stereotactic biopsy (CESB) offers a new alternative and has become commercially available since 2020. This narrative review will outline patient selection, the procedure, important considerations when performing CESB, and an overview of current literature.

Original language	English
Article number	111768
Journal	European Journal of Radiology
Volume	181
DOIs	https://doi.org/10.1016/j.ejrad.2024.111768
Publication status	Published - 1 Dec 2024

Keywords

Biopsy
Breast neoplasm
Contrast agents
Mammography

Access to Document

10.1016/j.ejrad.2024.111768

Cite this

@article{d3d1a44f70e644b2b828a51386ce1f3d,

title = "Contrast-Enhanced Stereotactic Biopsy (CESB): Patient selection and practical considerations",

abstract = "Since its introduction in 2012, contrast-enhanced mammography (CEM) has shown increased clinical relevance as a diagnostic tool in breast imaging. Its diagnostic accuracy is on par with breast MRI, rendering it a viable and potentially cost-effective alternative for breast MRI indications, especially in areas with lower accessibility to MRI. Like MRI, CEM occasionally shows {\textquoteleft}CEM-only{\textquoteright} lesions, i.e., areas of contrast enhancement without corresponding findings on low-energy images, ultrasound, or digital tomosynthesis. The current workaround usually consists of performing MRI-guided biopsy. However, contrast-enhanced stereotactic biopsy (CESB) offers a new alternative and has become commercially available since 2020. This narrative review will outline patient selection, the procedure, important considerations when performing CESB, and an overview of current literature.",

keywords = "Biopsy, Breast neoplasm, Contrast agents, Mammography",

author = "Lobbes, {M. B.I.} and J. Theunissen and A. Valentijn-Morsing and Y. Vissers and L. Bouwman",

note = "Publisher Copyright: {\textcopyright} 2024 Elsevier B.V.",

year = "2024",

month = dec,

day = "1",

doi = "10.1016/j.ejrad.2024.111768",

language = "English",

volume = "181",

journal = "European Journal of Radiology",

issn = "0720-048X",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Contrast-Enhanced Stereotactic Biopsy (CESB)

T2 - Patient selection and practical considerations

AU - Lobbes, M. B.I.

AU - Theunissen, J.

AU - Valentijn-Morsing, A.

AU - Vissers, Y.

AU - Bouwman, L.

PY - 2024/12/1

Y1 - 2024/12/1

N2 - Since its introduction in 2012, contrast-enhanced mammography (CEM) has shown increased clinical relevance as a diagnostic tool in breast imaging. Its diagnostic accuracy is on par with breast MRI, rendering it a viable and potentially cost-effective alternative for breast MRI indications, especially in areas with lower accessibility to MRI. Like MRI, CEM occasionally shows ‘CEM-only’ lesions, i.e., areas of contrast enhancement without corresponding findings on low-energy images, ultrasound, or digital tomosynthesis. The current workaround usually consists of performing MRI-guided biopsy. However, contrast-enhanced stereotactic biopsy (CESB) offers a new alternative and has become commercially available since 2020. This narrative review will outline patient selection, the procedure, important considerations when performing CESB, and an overview of current literature.

AB - Since its introduction in 2012, contrast-enhanced mammography (CEM) has shown increased clinical relevance as a diagnostic tool in breast imaging. Its diagnostic accuracy is on par with breast MRI, rendering it a viable and potentially cost-effective alternative for breast MRI indications, especially in areas with lower accessibility to MRI. Like MRI, CEM occasionally shows ‘CEM-only’ lesions, i.e., areas of contrast enhancement without corresponding findings on low-energy images, ultrasound, or digital tomosynthesis. The current workaround usually consists of performing MRI-guided biopsy. However, contrast-enhanced stereotactic biopsy (CESB) offers a new alternative and has become commercially available since 2020. This narrative review will outline patient selection, the procedure, important considerations when performing CESB, and an overview of current literature.

KW - Biopsy

KW - Breast neoplasm

KW - Contrast agents

KW - Mammography

U2 - 10.1016/j.ejrad.2024.111768

DO - 10.1016/j.ejrad.2024.111768

M3 - Comment/Letter to the editor

SN - 0720-048X

VL - 181

JO - European Journal of Radiology

JF - European Journal of Radiology

M1 - 111768

ER -

Contrast-Enhanced Stereotactic Biopsy (CESB): Patient selection and practical considerations

Abstract

Keywords

Access to Document

Fingerprint

Cite this